Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 665 participants.

Also called NCT01631227

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 665 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01631227
  • EudraCT 2010-019432-12
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, Russia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01631227. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-05-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Eprosartan
Intervention (Drug)
Eprosartan Mesylate
Intervention (Drug)
Placebo Eprosartan mesylate
Intervention (Drug)
Placebo Eprosartan
Lead sponsor
Abbott (class: industry)
Collaborator
Quintiles, Inc. (class: industry)
Collaborator
Synexus (class: other)
Collaborator
author! et al. BV (class: not stated)

Record details

Record id
cardio:ct-nct01631227
Content hash
36ae24da9ea51654362bd034ebd9a4d9daa317f0a3ea87e80e0d0acab6f9acfe